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Abstract
Background: Tools for plague diagnosis and surveillance are not always available and affordable in most of the countries
affected by the disease. Yersinia pestis isolation for confirmation is time-consuming and difficult to perform under field
conditions. Serologic tests like ELISA require specific equipments not always available in developing countries. In addition to
the existing rapid test for antigen detection, a rapid serodiagnostic assay may be useful for plague control.
Methods/Principal Findings: We developed two rapid immunochromatography-based tests for the detection of antibodies
directed against F1 antigen of Y. pestis. The first test, SIgT, which detects total Ig (IgT) anti-F1 in several species (S) (human
and reservoirs), was developed in order to have for the field use an alternative method to ELISA. The performance of the
SIgT test was evaluated with samples from humans and animals for which ELISA was used to determine the presumptive
diagnosis of plague. SIgT test detected anti-F1 Ig antibodies in humans with a sensitivity of 84.6% (95% CI: 0.76–0.94) and a
specificity of 98% (95% CI: 0.96–1). In evaluation of samples from rodents and other small mammals, the SlgT test had a
sensitivity of 87.8% (95% CI: 0.80–0.94) and a specificity of 90.3% (95% CI: 0.86–0.93). Improved performance was obtained
with samples from dogs, a sentinel animal, with a sensitivity of 93% (95% CI: 0.82–1) and a specificity of 98% (95% CI: 0.95–
1.01). The second test, HIgM, which detects human (H) IgM anti-F1, was developed in order to have another method for
plague diagnosis. Its sensitivity was 83% (95% CI: 0.75–0.90) and its specificity about 100%.
Conclusion/Significance: The SIgT test is of importance for surveillance because it can detect Ig antibodies in a range of
reservoir species. The HIgM test could facilitate the diagnosis of plague during outbreaks, particularly when only a single
serum sample is available.
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Introduction
Plague, a bacterial infection caused by Yersinia pestis, is essentially
a zoonosis of small mammals such as rodents. It is occasionally
transmitted to man by the bite of an infective flea [1]. The bubonic
form in humans can evolve rapidly to pneumonic form if not
treated early. Plague is an acute, often fatal, and potentially
epidemic disease. Accordingly, plague is classified as a class I
notifiable disease, subject to International Health Regulations [2].
Plague remains a serious problem for international public health.
Small outbreaks of plague continue to occur throughout the world,
and at least 2000 cases of plague are reported annually [3]. The
disease has displayed recrudescence and geographical extension in
Madagascar [4,5]. It reappeared in Algeria in June 2003 after an
absence of almost 60 years [6], and decreased in Vietnam in 2003
[7]. No natural foci of plague have been described in Algeria [8]
while in Vietnam plague persists in wild animal reservoirs and is
subject to an intensified monitoring program.
Bubonic plague is the major form of the disease encountered in
the modern plague outbreaks. It affects mainly rural people in
developing countries, whose level of education is very low. In
Madagascar, plague foci matches with the poorest rural area with
the most vulnerable population [9,10]. Re-emergence of plague is
associated with low sanitary condition, waste, rats abundance and
proximity to rodents [11]. In fact that plague currently affects poor
and vulnerable people, development of simple and affordable test
which may help and contribute to the control of the disease should
be taken in consideration.
The control of plague involves diagnosis and recognition of the
disease [2]. For diagnosis, plague confirmation can be done by
bacteriological culture (isolation of Y. pestis strain), by rapid
diagnostic test (RDT) for F1 antigen detection (in endemic area
www.plosntds.org 1 April 2009 | Volume 3 | Issue 4 | e421without other confirmatory test) or by serology (four-fold rise in
anti-F1 antibody titre in paired serum samples) [12].
The isolation of Y. pestis from clinical sample (pus of bubo,
sputum) requires a laboratory with at least level II biosafety put
into place [13]. Moreover, bacteriology is time-consuming,
expensive and sensitive to the presence of contaminants, to patient
treatment and to delays in specimen transport.
A RDT for the detection of F1 antigen, a capsular antigen of Y.
pestis, was recently developed and could be used on bubo aspirate,
sputum, sera, urine and organs removed post mortem [14]. This
test may be useful for confirming clinical diagnosis and triggering
alerts. It performed particularly well with bubo aspirate when
bubonic plague was suspected. The development of this RDT
constitutes a major advance in plague diagnosis, particularly in
countries with poor medical infrastructures [15].
The serology for the detection of anti-F1 plague antibodies plays
an important role in confirming plague diagnosis. Indeed, during
the last outbreak of pneumonic plague in the Democratic Republic
of Congo (DRC) in 2005, plague diagnosis was confirmed by
evidence of seroconversion based on the anti-F1 IgG titre in paired
serum samples [16]. The ELISA method is essential for
retrospective confirmation when the causal agent cannot be
isolated and also when only serum is available.
When neither the most appropriate specimen nor the pair of
sera were available, the plague confirmation is ‘‘compromised’’. A
rapid test which can be performed with a unique serum collected
during the early stage of the infection would be very helpful for the
biological diagnosis.
For the surveys of plague infection foci, the sero-epidemiolog-
ical or sero-epizootic investigations of anti-F1 antibody preva-
lence in human or animal population could be achieved. The
species involved in the plague cycle have been identified in
Madagascar and Viet Nam, but this is not necessarily the case in
other countries, such as Algeria. ELISA is an efficient tool for the
serology but it is difficult to carry out in field either for diagnosis
or for surveillance. It requires specific equipment, expensive
consumables and specific antibodies to each species for the
revelation of anti-F1 to be detected. The available ELISA for
human and rodent IgG detection were respectively 91.4% and
100% sensitive and 98.5% and 100% specific [17,18]. A rapid
test for anti-F1 IgG antibody detection with a ‘‘half-dipstick’’
format has been described for humans and animal reservoirs. Its
sensitivity was 94.3% and its specificity 89.2% [19]. This format
showed only a test line. A second line, absent from this test, and
usually used for attesting the validity of the strip (control line) in
immunocrhromatographic assays is of great importance in result
interpretations.
There is still a need to develop a simple, rapid and cost-effective
test for the detection of plague-specific antibodies. First, a test
which can replace the ELISA and which can be used in a large-
scale in the field would be beneficial. Second, another test which
can be used for biological diagnosis of plague would be very
helpful.
We aimed to develop two immunochromatography-based tests
(dipstick). The SIgT test is able to detect total (T) anti-F1
immunoglobulin (Ig) in different species (S) (human and animal
reservoirs). It was compared with ELISA. The SIgT test could
have major applications in epidemiological investigations of plague
and for surveillance. The HIgM test is able to detect human (H)
anti-F1 IgM. Performance of the test with sera from individual
with known status of plague was determined.
Materials and Methods
Development of the rapid serodiagnostic test
We developed two rapid tests based on a one-step, vertical-flow
immunochromatography. The test consisted of a reaction pad, a
conjugate pad and the absorbent pads. The reaction pad consists
of a nitrocellulose membrane, with a pore size of 5 mm (Whatman
International, Chateau Giron - France). The BioDot machine
(BioDot, Irvine, California) was used to spray a line of Protein A
(Pharmacia, Sweden) at a concentration of 2.5 mg/ml to capture
Ig for SIgT test or a line of anti-human IgM (m) at a concentration
of 2 mg/ml (P.A.R.I.S, Compie `gne – France) to capture human
IgM for HIgM test. Protein A possesses two distinct Ig-binding
domains, one that binds the Fc region of IgG and the other that
binds the Fab region of Ig [20]. A second line of monoclonal anti-
F1 antibody (MAbB18-1) was also sprayed on the upper part of the
nitrocellulose. This Anti-F1 antibody reacts with the gold particles-
F1 antigen conjugate and form a second reaction (control line),
indicating that the test has been correctly performed. The control
line attests the validity of the test and should always appear.
The conjugate pad consists of a polyester Accuflow P (Whatman
Schleicher & Schuell, England). The colloidal gold particles
(40 nm diameter) were conjugated to F1 antigen by the British
Biocell International (British Biocell International Cardiff, UK).
The polyester was soaked in F1 conjugated at OD=3 and was
overnight lyophilised.
The absorbent pads (sample and wicking pads) consist of
cellulose filter paper (Schleicher and Schuell, Ecquevelly - France).
The sample pad was soaked in blocking buffer (0.1 M sodium
borate supplemented with 1% Triton X-100) and overnight dried.
The wicking pad was not processed prior to use.
A membrane-based immunochromatographic card was pre-
pared by fixing the different pads onto a plastic card with double-
sided sticky tape (Adhesives Research Ltd, Melville House United
Kingdom): the reaction pad in the middle, the conjugate pad
under the sample pad at the bottom and the wicking pad at the top
of the card (Figure 1). The dipstick were trimmed to a width of
5 mm with the BioDot cutting machine and stored in a waterproof
bag at 4uC.
The dipstick test was performed on sera or seropads (blood on
blotting paper). Sera were previously diluted ten times in distilled
water. For seropads, one pastille was soaked in 200 ml of distilled
water and incubated for one hour at 37uC or at room temperature.
This step allows the elution of the serum from the filter. The test
Author Summary
Plague is due to the bacterium Yersinia pestis.I ti s
accidentally transmitted to humans by the bite of infected
fleas. Currently, approximately 20 developing countries
with very limited infrastructure are still affected. A plague
case was defined according to clinical, epidemiological and
biological features. Rapid diagnosis and surveillance of the
disease are essential for its control. Indeed, the delay of
treatment is often rapidly fatal for patients and outbreaks
may occur. Bubo aspirate is the most appropriate
specimen in case of bubonic plague, but its collection is
not always feasible. The main current biological approach-
es for the diagnosis of human plague are F1 antigen
detection, serology for antibody detection by ELISA and Y.
pestis isolation. The biological diagnosis of plague remains
a challenge because the clinical signs are not specific. In
this study, we developed some simple, rapid and
affordable tests able to detect specific plague antibodies.
These tests can be used as alternative methods for plague
diagnosis in the field and for plague surveillance.
Plague Serodiagnosis by Rapid Test
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sample. Diluted serum samples containing antibody absorbed
from the bottom of the dipstick bound to the conjugated antigen,
and the antigen-antibody binding formed complexes moved by
capillary action into the nitrocellulose membrane. The complexes
reacted with the immobilised protein A, generating a signal.
Excess of the conjugate moved on the nitrocellulose and bound to
the anti-F1 Mab, giving a second signal corresponding to the
control line (Figure 2). Results were read after 15 minutes. Two
pink lines appeared in positive sample and a single pink line in
negative one. If the control line is absent, the test is invalid.
The shelf life of the strip for long-term storage was assessed by
testing serial dilution of the positive control sera with the dipsticks
stored at 60uC twice per week for three weeks. Storage at 60uC for
three weeks is equivalent of two years at room temperature [21].
The detection limit of the tests was obtained by testing in duplicate
serial dilutions of the positive control. For SIgT test, it was
expressed as the lowest concentration of MAb anti-F1 G6-18
giving positive result. For HIgM test, the detection limit was
expressed as the highest titre of sera with positive result.
Evaluation of the plague serodiagnostic tests
The tests were evaluated on human and canine stored sera at
Institut Pasteur de Madagascar and on small mammal samples
freshly collected by the Pasteur Institutes of Algeria, Madagascar
and Nha-Trang or from their frozen collection. The human
samples tested were anonymous frozen sera from the collection of
Institut Pasteur of Madagascar. Samples without turbidity, with
sufficient quantity and with clearly identification number were
selected and blind tests were performed. A total of 288 sera from
the following groups were included in the study:
Sera from suspected human plague. Human samples from
plague suspected cases (n=131) were taken from sera collected
during sero-epidemiological investigation in 1999 at CHU
Androva-Mahajanga, the only coast plague focus in Madagascar
and in 2002 at Ankazobe, one of the active foci in Antananarivo
province. These sera were sampled within the framework of the
routine plague diagnosis during outbreaks. Suspect plague was
defined as compatible clinical and epidemiological features [2].
Negative control sera. Frozen sera collected from
individuals in plague-free area were used as negative controls
(n=71): 24 sera from Fort-Dauphin in Madagascar collected in
2000 during malaria surveillance, 23 sera from Comoros collected
in 1999 during cholera outbreak and 24 sera from Seychelles
collected in 1997 during arbovirosis surveillance.
Sera from patient with others infectious diseases. To
assess the cross-reaction with other bacterial or parasitic infections
prevalent in Madagascar, samples (n=86) collected from patients
with schistosomiasis, cysticercosis, toxoplasmosis, hepatitis B,
hepatitis C, streptococcosis and with unknown diseases were
tested. These sera were sampled within the framework of the
evaluation of a serodiagnostic test in 1997.
Evaluation on specimens from dogs (n=63) and from rodent or
small-mammals (n=352) specimens was performed by testing sera
or seropads from animals in plague foci or in areas non endemic
for plague in Madagascar, Viet Nam and Algeria. Canine samples
were collected in 1999 within the framework of diagnosis tool
development, while rodent samples were collected during plague
monitoring in rodent populations. For small mammal sera
collection, we adhered to our institutional guidelines for animal
husbandry and experiments.
For HIgM test evaluation, sensitivity was studied with 23 acute-
phase sera specimen from bacteriologically-confirmed plague
cases. Only the 26 negative controls from Madagascar and the
86 sera from patients with others infectious diseases were used for
studying the specificity of this HIgM test.
Reference tests
For SIgT test, as the purpose of this test is to be an alternative
method to the ELISA in the field, ELISA was used as reference
methods. Both methods were performed with each sample.
Human sera were tested by human IgG anti-F1 ELISA. The
sensitivity of this ELISA was 91.4%, and its specificity was 98.5%
[17]. Small mammals and dogs sera were tested according to a
previously described ELISA [18]. For rodent sera, revelation used
a goat anti-IgG (H+L) rat Horse Radish-Peroxidase H.R.P
(Sigma-Aldrich, USA) and for insectivore and dog samples, a
peroxydase conjugated protein A. Samples were considered
positive when the absorbance was above the defined threshold.
ELISA for rodent and insectivore was standardized by testing
sera from experimentally infected animals and from animals
caught in plague-free areas. For rodent ELISA, its’ sensitivity and
specificity were 100% [18]. For dogs, sera collected from animals
in plague-endemic and plague-free areas were used to standardize
the ELISA. The specificity of a positive ELISA-anti-F1 for this
species was confirmed by F1 antigen-inhibition. Dog ELISA had a
specificity of 97.3%. Sensitivity wasn’t determined because dogs’
positive controls were not available.
For HIgM test, the evaluation was carried out with sera from
individual of known plague status according to the biological
diagnosis by bacteriology (culture) [13]. The purpose was to have
another method for plague diagnosis when bubo aspiration or
sputum for the culture or the pair of sera for the serology are not
available. We compare the results of HIgM test with plague status.
Figure 1. Different components of the dipstick.
doi:10.1371/journal.pntd.0000421.g001
Plague Serodiagnosis by Rapid Test
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The data, such identification number of the sample and the
results of the two compared tests, were entered in Microsoft Excel
sheet and analysed by Pivot Table reports. Sensitivity (Se) and
specificity (Sp) estimates are given as percentages with 95%
confidence interval.
Ethical consideration
The use of the human sera from the collection of Institut Pasteur
de Madagascar, including the sera from plague patients, the sera
from individual in plague–free area and the sera from patients
affected by others diseases, was approved by the ethics committee
of the Madagascar Ministry of Health.
Results
SIgT test was able to detect total anti-F1 antibodies in both
humans and animal reservoirs species. The lower detection limit of
SIgT test was 20 ng/ml of anti-F1 MAb (G6-18). The shelf-life
study indicated that SIgT test was stable after storage for 14 days
at 60uC, and its threshold increased to 40 ng/ml after 21 days at
60uC. The application of SIgT test to serum samples from several
species was summarized in Table 1. HIgM test was able to detect
human anti-F1 IgM in an unique serum. With the positive control
sera, the highest IgM titre detected by this test was 1/10,000. The
shelf-life study of HIgM test indicated that its performance was
unaffected by storage at 60uC for 21 days. During the evaluation
process, no invalid tests i.e. no tests lacked the control line were
observed.
Application of SIgT test to human sera
We tested a total of 131 sera from human clinically suspected
plague from which 65 were positive by ELISA. Compared to
ELISA, the SIgT test gave 55/65 (84.6%) positive results. Among
ten SIgT-negative and ELISA-positive samples, six had a low IgG
titre by ELISA and four were sera collected early. Among the 66
negative sera by ELISA, 63 were also negative with SIgT test and
3 were positive (Figure 3). Among the 71 negative controls tested;
70 were negative by SIgT test. The specificity of SIgT test was
assessed by testing 86 samples from patients with other infectious
diseases prevalent in Madagascar: 19 patients with schistosomiasis,
10 patients with cysticercosis, 14 patients with toxoplasmosis, 10
patients with hepatitis B, 10 patients with hepatitis C, 10 patients
with streptococcosis and 13 patients with unknown diseases. All
these sera were negative. The SIgT test performed on human
samples and compared to ELISA had a sensitivity of 84.6% with
95% CI between 0.76 and 0.94 and a specificity of 98% with 95%
CI between 0.96 and 1. It had a positive predictive value (PPV) of
Figure 2. Principle of the dipstick test. A: SIgT test, B: HIgM test, C: Negative test, D: Positive test for Ig anti-F1, E: Positive test for IgM anti-F1.
doi:10.1371/journal.pntd.0000421.g002
Plague Serodiagnosis by Rapid Test
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plague prevalence estimated to 0.6% under endemic situations in
Madagascar highlands.
Application of SIgT test to small mammals sera
SIgT test was evaluated with 352 sera from animal reservoirs of
plague: 88 small mammals (Rattus rattus, Rattus norvegicus) from
Madagascar, 134 from Viet Nam (genera Rattus, Mus, Suncus) and
130 from Algeria (genera Lemniscomys, Psamommys, Atelerix). When
compared to ELISA, SIgT test had a sensitivity of 87.8% with
95% CI between 0.80 and 0.94 and a specificity of 90.3% with
95% CI between 0.86 and 0.93. It had a PPV of 70.6% and a
NPV of 96.5% with rodent plague prevalence estimated to 10.5 in
context of highland endemic foci.
Application of SIgT test to canine sera
Dogs respond to Y. pestis infection by producing specific
antibodies against the F1 antigen of Y. pestis. Sixty three samples
from endemic (14 sera) and from non-endemic (49 sera) areas of
Madagascar were tested. Compared to ELISA, SIgT test had a
sensitivity of 93% with 95% CI between 0.82 and 1.0 and a
specificity of 98% with 95% CI between 0.95 and 1. It had a PPV
of 92.8% and a NPV of 98% with a plague prevalence estimated
to 23.8% under plague endemic area situation.
Evaluation of HIgM test
We evaluated HIgM test with 23 acute-phase sera from
bacteriologically-confirmed plague patient and 110 plague-nega-
tive (24 negative control from Madagascar and 86 with others
Figure 3. STARD flow diagram for the evaluation of SIgT test on plague suspected cases.
doi:10.1371/journal.pntd.0000421.g003
Table 1. Comparison of SIgT test and ELISA for human, small mammal and dog serum samples.
SIgT test ELISA
Human Small mammal Dog
N (n=223) P (n=65) N (n=278) P (n=74) N (n=49) P (n=14)
N 219 (98.2%) 10 (15.4%) 251 (90.3%) 9 (12.2%) 48 (98%) 1 (7.2%)
P 4 (1.8%) 55 (84.6%) 27 (9.7%) 65 (87.8%) 1 (2%) 13 (92.8%)
N : Negative, P: Positive, n: sample number.
doi:10.1371/journal.pntd.0000421.t001
Plague Serodiagnosis by Rapid Test
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Institut Pasteur de Madagascar. Results of HIgM tests are
presented according to the patient status for plague (Table 2).
HIgM test gave 19/23 positive results. Among the 4 discordant
results (HIgM test negative but plague status confirmed by
bacteriology), 2 samples were collected within three days after
the disease onset. HIgM test was found to have a sensitivity of 83%
with 95% CI between 0.75 and 0.90 and a specificity of 100%.
This test had a PPV of 100% and a NPV of 96.49% with plague
prevalence estimated to 0.6% stated above. No cross-reactivity
with HIgM test was detected within the 86 sera from patient
infected with other diseases.
Discussion
We developed and evaluated two tests for the qualitative
detection of plague anti-F1 antibodies in sera: the SIgT test for
total Ig anti-F1 antibodies during and after plague infection in
humans, rodents and other animals and the HIgM test for anti-F1
IgM in humans.
Using ELISA as reference method, SIgT test detected plague
antibodies in human with a sensitivity of 84.6% and a specificity of
98% according to the reference test ELISA which sensitivity and
specificity were respectively 91.4% and 98.5% [17]. By this
comparison, 3 discordant results SIgT positive-ELISA negative
were obtained with sera collected from bacteriologically-confirmed
plague cases. Of the 10 samples SIgT test negative-ELISA positive,
four sera were from bacteriologically-confirmed plague cases
(Figure 3). These are SIgT test false negative. The limitation of this
new test is about the low positive sample with ELISA that could be
negative by SIgT test. Although less sensitive (but specific), this
new test would be useful in case of plague outbreak since it could
give rapid information on the human plague situation in a studied
area. It is also particularly interesting for retrospective investiga-
tion when only serum is available.
In addition, since SIgT test detects plague-specific antibodies in
many species of animal reservoirs, it is suitable for large scale
serological survey of reservoirs in remote and impoverished areas
endemic for plague. This could help to determine the risk of
plague in a given zone, leading to a progress in disease prevention.
SIgT test, used for canine sera proved sensitive and specific
enough for this purpose, since it provided evidence of plague
antibodies production in 93% of the samples collected from area of
endemic plague, whereas over 98% of the samples from areas
considered free of plague tested negative. Indeed, dogs are useful
sentinels of plague prevalence, since animals living in or in
adjacent to areas endemic for plague may be in contact with Y.
pestis by infected flea bites or by consuming infected prey. They
may develop high antibody titre without plague symptoms [22].
Moreover it is easier to manage dogs than small mammals’
surveillance whose study is tedious (number of samples to be
collected and analysed).
HIgM test was developed for the detection of anti-F1 IgM in
humans to provide an alternative diagnostic method for plague,
particularly when serum is the only clinical specimen available.
HIgM test in plague confirmed cases gave a specificity of 100%
and a sensitivity of 83%. This low sensitivity will generate some
false negative results. However, of the 4 ‘‘false negative’’ samples; 2
were taken early (within 2 days after onset of the disease) before
IgM was likely to be detectable in blood and 2 were collected 1
week after the onset of the disease. Owing to its high specificity,
HIgM test could be used with significant advantage on serum
samples collected during the acute phase as early as three days
after onset of the disease. It could be performed with only a single
serum sample while plague diagnosis by ELISA usually need a pair
of sera (early and late sera collected at 4–6 weeks interval) [2].
Our aim was to develop some simple, rapid and affordable tools
for a large scale use in plague monitoring (seroepidemiological
investigations) and as an alternative test to ELISA.
In the majority of endemic area, particularly in Madagascar, the
poor sanitary and economic situation renders difficult the control
and surveillance of plague. Bacteriology techniques including
culture-isolation and mouse infection require appropriate labora-
tory. In developing countries, at the district level, simple tests like
the dipstick assay can be implemented in the health centres. Most
of the suspected cases of plague are detected in remote villages in
rural area. As soon as transport of specimen from these places to a
central laboratory is long and difficult, it is essential to possess an
alternative tool for plague diagnosis and surveillance on site.
A pilot assessment of the new tests by users at the periphery level
could be considered to define the utility and performance of these
tools in field conditions.
In conclusion, the rapid serodiagnostic tests developed in this
study are promising, not only for epidemiological studies, but also
for the surveillance of reservoirs and active foci and for plague
diagnosis. Application in case of bioterrorism attack can also be
considered as Y. pestis is recognized as biological weapon [23].
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